{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:28:05Z","timestamp":1793302085192,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00025\/4 (RG94521)"],"award-info":[{"award-number":["MC_UU_00025\/4 (RG94521)"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00025\/3 (RG94521)"],"award-info":[{"award-number":["MC_UU_00025\/3 (RG94521)"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antipsychotic drugs are the mainstay of treatment for schizophrenia and provide adjunct therapies for other prevalent psychiatric conditions, including bipolar disorder and major depressive disorder. However, they also induce debilitating extrapyramidal syndromes (EPS), such as Parkinsonism, in a significant minority of patients. The majority of antipsychotic drugs function as dopamine receptor antagonists in the brain while the most recent \u2018third\u2019-generation, such as aripiprazole, act as partial agonists. Despite showing good clinical efficacy, these newer agents are still associated with EPS in\u2009~\u20095 to 15% of patients. However, it is not fully understood how these movement disorders develop. Here, we combine clinically-relevant drug concentrations with mutliscale model systems to show that aripiprazole and its primary active metabolite induce mitochondrial toxicity inducing robust declines in cellular ATP and viability. Aripiprazole, brexpiprazole and cariprazine were shown to directly inhibit respiratory complex I through its ubiquinone-binding channel. Importantly, all three drugs induced mitochondrial toxicity in primary embryonic mouse neurons, with greater bioenergetic inhibition in ventral midbrain neurons than forebrain neurons. Finally, chronic feeding with aripiprazole resulted in structural damage to mitochondria in the brain and thoracic muscle of adult\n                    <jats:italic>Drosophila melanogaster<\/jats:italic>\n                    consistent with locomotor dysfunction. Taken together, we show that antipsychotic drugs acting as partial dopamine receptor agonists exhibit off-target mitochondrial liabilities targeting complex I.\n                  <\/jats:p>","DOI":"10.1186\/s13062-023-00375-9","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T05:02:40Z","timestamp":1690866160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors"],"prefix":"10.1186","volume":"18","author":[{"given":"Rachel E.","family":"Hardy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Injae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha H. Y.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Morone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Soleilhavoup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Travaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Serreli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Panman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Pryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"375_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"key":"375_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-25761-2_1","volume":"212","author":"R Kuepper","year":"2012","unstructured":"Kuepper R, Skinbjerg M, Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb Exp Pharmacol. 2012;212:1\u201326.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"375_CR3","first-page":"119","volume":"53","author":"PG Strange","year":"2001","unstructured":"Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 2001;53(1):119\u201333.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"375_CR4","first-page":"36","volume":"2","author":"M Mathews","year":"2005","unstructured":"Mathews M, et al. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry. 2005;2(3):36\u201341.","journal-title":"Psychiatry"},{"issue":"Suppl 3","key":"375_CR5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","volume":"13","author":"TR Barnes","year":"1998","unstructured":"Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol. 1998;13(Suppl 3):S49-57.","journal-title":"Int Clin Psychopharmacol"},{"key":"375_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/00006205-199211000-00018","author":"DT Blair","year":"1992","unstructured":"Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract. 1992. https:\/\/doi.org\/10.1097\/00006205-199211000-00018.","journal-title":"Nurse Pract"},{"key":"375_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","volume":"389","author":"D Savitt","year":"2018","unstructured":"Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35\u201342.","journal-title":"J Neurol Sci"},{"issue":"1","key":"375_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin HW, Chung SJ. Drug-induced Parkinsonism. J Clin Neurol. 2012;8(1):15\u201321.","journal-title":"J Clin Neurol"},{"issue":"Suppl 9","key":"375_CR9","first-page":"25","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65(Suppl 9):25\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"375_CR10","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0920-9964(98)00160-1","volume":"35","author":"DE Casey","year":"1999","unstructured":"Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(Suppl):S61-66.","journal-title":"Schizophr Res"},{"issue":"3","key":"375_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0924-9338(02)00647-8","volume":"17","author":"PM Llorca","year":"2002","unstructured":"Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eu Psychiatry. 2002;17(3):129\u201338.","journal-title":"Eu Psychiatry"},{"key":"375_CR12","unstructured":"MEPS (2008\u20132018) Medical Expenditure Panel Survey (Rockville)."},{"key":"375_CR13","first-page":"Cd006617","volume":"1","author":"J Bhattacharjee","year":"2008","unstructured":"Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typicals for schizophrenia. Cochr Database Syst Rev. 2008;1:Cd006617.","journal-title":"Cochr Database Syst Rev"},{"issue":"4","key":"375_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","volume":"12","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655\u201362.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"375_CR15","doi-asserted-by":"publisher","first-page":"12509","DOI":"10.1038\/s41598-018-30794-y","volume":"8","author":"A Frank","year":"2018","unstructured":"Frank A, Kiss DJ, Keseru GM, Stark H. Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor. Sci Rep. 2018;8(1):12509.","journal-title":"Sci Rep"},{"issue":"1","key":"375_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2045125316672136","volume":"7","author":"JS Frankel","year":"2017","unstructured":"Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therap Adv Psychopharmacol. 2017;7(1):29\u201341.","journal-title":"Therap Adv Psychopharmacol"},{"issue":"15","key":"375_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s40265-019-01189-8","volume":"79","author":"JM Azorin","year":"2019","unstructured":"Azorin JM, Simon N. Dopamine receptor partial agonists for the treatment of bipolar disorder. Drugs. 2019;79(15):1657\u201377.","journal-title":"Drugs"},{"issue":"12","key":"375_CR18","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14656566.2019.1626825","volume":"20","author":"LA Bartram","year":"2019","unstructured":"Bartram LA, Lozano J, Coury DL. Aripiprazole for treating irritability associated with autism spectrum disorders. Expert Opin Pharmacother. 2019;20(12):1421\u20137.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"375_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1080\/03007995.2018.1519317","volume":"34","author":"K Kamijima","year":"2018","unstructured":"Kamijima K, Yasuda M, Yamamura K, Fukuta Y. Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Curr Med Res Opin. 2018;34(12):2105\u201312.","journal-title":"Curr Med Res Opin"},{"key":"375_CR20","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.10m01008gry","author":"AS Robb","year":"2011","unstructured":"Robb AS, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6\u201317 years old):results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord. 2011. https:\/\/doi.org\/10.4088\/PCC.10m01008gry.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"9","key":"375_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40263-016-0367-y","volume":"30","author":"C Bernagie","year":"2016","unstructured":"Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs. 2016;30(9):807\u201318.","journal-title":"CNS Drugs"},{"issue":"4","key":"375_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1017\/S1092852918001104","volume":"24","author":"HA Nasrallah","year":"2019","unstructured":"Nasrallah HA, et al. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395\u2013403.","journal-title":"CNS Spectr"},{"issue":"2","key":"375_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JCP.0b013e31819a4bd5","volume":"29","author":"C Lungu","year":"2009","unstructured":"Lungu C, et al. Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol. 2009;29(2):185\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"375_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.09l05836gre","volume":"71","author":"JH Friedman","year":"2010","unstructured":"Friedman JH. Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient. J Clin Psychiatry. 2010;71(5):652\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"375_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/ncb1881","volume":"11","author":"A Herrero-Mendez","year":"2009","unstructured":"Herrero-Mendez A, et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC\/C-Cdh1. Nat Cell Biol. 2009;11(6):747\u201352.","journal-title":"Nat Cell Biol"},{"key":"375_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","volume":"49","author":"Y Wu","year":"2019","unstructured":"Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion. 2019;49:35\u201345.","journal-title":"Mitochondrion"},{"issue":"8649","key":"375_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","volume":"1","author":"AH Schapira","year":"1989","unstructured":"Schapira AH, et al. Mitochondrial complex I deficiency in Parkinson\u2019s disease. Lancet. 1989;1(8649):1269.","journal-title":"Lancet"},{"issue":"8653","key":"375_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(89)90291-2","volume":"2","author":"LA Bindoff","year":"1989","unstructured":"Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD Jr, Turnbull DM. Mitochondrial function in Parkinson\u2019s disease. Lancet. 1989;2(8653):49.","journal-title":"Lancet"},{"issue":"3","key":"375_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-017-1794-7","volume":"135","author":"IH Flones","year":"2018","unstructured":"Flones IH, et al. Neuronal complex I deficiency occurs throughout the Parkinson\u2019s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol. 2018;135(3):409\u201325.","journal-title":"Acta Neuropathol"},{"issue":"5674","key":"375_CR30","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente EM, et al. Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science. 2004;304(5674):1158\u201360.","journal-title":"Science"},{"issue":"6676","key":"375_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605\u20138.","journal-title":"Nature"},{"key":"375_CR32","first-page":"49","volume":"100","author":"JW Langston","year":"1984","unstructured":"Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates\u2013clinical and experimental aspects. Acta Neurol Scand Suppl. 1984;100:49\u201354.","journal-title":"Acta Neurol Scand Suppl"},{"key":"375_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.brainres.2016.11.020","volume":"1655","author":"ZN Zhang","year":"2017","unstructured":"Zhang ZN, et al. Subcutaneous rotenone rat model of Parkinson\u2019s disease: Dose exploration study. Brain Res. 2017;1655:104\u201313.","journal-title":"Brain Res"},{"issue":"8","key":"375_CR34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1517\/17425255.2014.939628","volume":"10","author":"Y Will","year":"2014","unstructured":"Will Y, Dykens J. Mitochondrial toxicity assessment in industry\u2013a decade of technology development and insight. Expert Opin Drug Metab Toxicol. 2014;10(8):1061\u20137.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"375_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/pr.113.007450","volume":"65","author":"J Uetrecht","year":"2013","unstructured":"Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013;65(2):779\u2013808.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"375_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","volume":"97","author":"LD Marroquin","year":"2007","unstructured":"Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci. 2007;97(2):539\u201347.","journal-title":"Toxicol Sci"},{"issue":"3","key":"375_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/15622970701361255","volume":"9","author":"KM Kirschbaum","year":"2008","unstructured":"Kirschbaum KM, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9(3):212\u20138.","journal-title":"World J Biol Psychiatry"},{"issue":"10","key":"375_CR38","doi-asserted-by":"publisher","first-page":"13790","DOI":"10.1021\/acsomega.8b02057","volume":"3","author":"K Sakurama","year":"2018","unstructured":"Sakurama K, et al. Analysis of the binding of aripiprazole to human serum albumin: the importance of a Chloro-group in the chemical structure. ACS Omega. 2018;3(10):13790\u20137.","journal-title":"ACS Omega"},{"issue":"1","key":"375_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","volume":"8","author":"DA Sykes","year":"2017","unstructured":"Sykes DA, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors. Nat Commun. 2017;8(1):763.","journal-title":"Nat Commun"},{"issue":"12","key":"375_CR40","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/mds.25135","volume":"27","author":"JP Bolam","year":"2012","unstructured":"Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord. 2012;27(12):1478\u201383.","journal-title":"Mov Disord"},{"issue":"2","key":"375_CR41","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.neuron.2017.12.016","volume":"97","author":"JM Donlea","year":"2018","unstructured":"Donlea JM, et al. Recurrent circuitry for balancing sleep need and sleep. Neuron. 2018;97(2):378-389.e374.","journal-title":"Neuron"},{"issue":"11","key":"375_CR42","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/nn.3238","volume":"15","author":"T Ueno","year":"2012","unstructured":"Ueno T, et al. Identification of a dopamine pathway that regulates sleep and arousal in Drosophila. Nat Neurosci. 2012;15(11):1516\u201323.","journal-title":"Nat Neurosci"},{"issue":"1","key":"375_CR43","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1038\/cddis.2012.205","volume":"4","author":"AC Costa","year":"2013","unstructured":"Costa AC, Loh SH, Martins LM. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1\/parkin model of Parkinson\u2019s disease. Cell Death Dis. 2013;4(1):e467.","journal-title":"Cell Death Dis"},{"issue":"2","key":"375_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15376510309846","volume":"13","author":"A Nazir","year":"2003","unstructured":"Nazir A, Mukhopadhyay I, Saxena DK, Chowdhuri DK. Evaluation of the no observed adverse effect level of solvent dimethyl sulfoxide in drosophila melanogaster. Toxicol Mech Methods. 2003;13(2):147\u201352.","journal-title":"Toxicol Mech Methods"},{"issue":"4","key":"375_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","volume":"193","author":"DD Miller","year":"2008","unstructured":"Miller DD, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193(4):279\u201388.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"375_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740330902835493","volume":"8","author":"CU Pae","year":"2009","unstructured":"Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009;8(3):373\u201386.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"375_CR47","first-page":"418","volume":"41","author":"S Eaves","year":"2016","unstructured":"Eaves S, Rey JA. Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. Pharm Therap. 2016;41(7):418\u201322.","journal-title":"Pharm Therap"},{"issue":"1","key":"375_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12888-017-1459-z","volume":"17","author":"HA Nasrallah","year":"2017","unstructured":"Nasrallah HA, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305.","journal-title":"BMC Psychiatry"},{"key":"375_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01665-8","author":"T Cikankova","year":"2019","unstructured":"Cikankova T, Fisar Z, Bakhouche Y, Luptak M, Hroudova J. In vitro effects of antipsychotics on mitochondrial respiration. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2019. https:\/\/doi.org\/10.1007\/s00210-019-01665-8.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"11","key":"375_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/BF02980205","volume":"26","author":"JS Modica-Napolitano","year":"2003","unstructured":"Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharmacal Res. 2003;26(11):951\u20139.","journal-title":"Arch Pharmacal Res"},{"key":"375_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.toxlet.2017.03.018","volume":"272","author":"E Elmorsy","year":"2017","unstructured":"Elmorsy E, et al. Effect of antipsychotics on mitochondrial bioenergetics of rat ovarian theca cells. Toxicol Lett. 2017;272:94\u2013100.","journal-title":"Toxicol Lett"},{"issue":"4","key":"375_CR52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0028-3908(98)00215-9","volume":"38","author":"S Balijepalli","year":"1999","unstructured":"Balijepalli S, Boyd MR, Ravindranath V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology. 1999;38(4):567\u201377.","journal-title":"Neuropharmacology"},{"issue":"5","key":"375_CR53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.410330516","volume":"33","author":"C Burkhardt","year":"1993","unstructured":"Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol. 1993;33(5):512\u20137.","journal-title":"Ann Neurol"},{"issue":"6","key":"375_CR54","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acs.jnatprod.9b01224","volume":"83","author":"DA Russell","year":"2020","unstructured":"Russell DA, et al. Hydroxylated rotenoids selectively inhibit the proliferation of prostate cancer cells. J Nat Prod. 2020;83(6):1829\u201345.","journal-title":"J Nat Prod"},{"issue":"9","key":"375_CR55","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","volume":"29","author":"A de Bartolomeis","year":"2015","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29(9):773\u201399.","journal-title":"CNS Drugs"},{"issue":"2","key":"375_CR56","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","volume":"27","author":"F Yokoi","year":"2002","unstructured":"Yokoi F, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002;27(2):248\u201359.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"375_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","volume":"57","author":"S Kapur","year":"2000","unstructured":"Kapur S, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 10","key":"375_CR58","first-page":"15","volume":"60","author":"G Remington","year":"1999","unstructured":"Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry. 1999;60(Suppl 10):15\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"375_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/PL00014189","volume":"249","author":"S Kasper","year":"1999","unstructured":"Kasper S, et al. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 4):83\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"375_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jcph.979","volume":"58","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of Brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol. 2018;58(1):74\u201380.","journal-title":"J Clin Pharmacol"},{"key":"375_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","volume":"10","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327\u201338.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"375_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0091270003261901","volume":"44","author":"S Mallikaarjun","year":"2004","unstructured":"Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44(2):179\u201387.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"375_CR63","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","volume":"59","author":"KM Kirschbaum","year":"2010","unstructured":"Kirschbaum KM, et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology. 2010;59(6):474\u20139.","journal-title":"Neuropharmacology"},{"issue":"6","key":"375_CR64","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1176\/ajp.156.6.885","volume":"156","author":"J Kornhuber","year":"1999","unstructured":"Kornhuber J, et al. Persistence of haloperidol in human brain tissue. Am J Psychiatry. 1999;156(6):885\u201390.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"375_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2009.01.011","volume":"110","author":"JS Wang","year":"2009","unstructured":"Wang JS, et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res. 2009;110(1\u20133):90\u20134.","journal-title":"Schizophr Res"},{"issue":"4","key":"375_CR66","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/jimd.12196","volume":"43","author":"MC De Vries","year":"2020","unstructured":"De Vries MC, et al. Safety of drug use in patients with a primary mitochondrial disease: an international Delphi-based consensus. J Inherit Metab Dis. 2020;43(4):800\u201318.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"375_CR67","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00702-008-0121-9","volume":"115","author":"K Gaweda-Walerych","year":"2008","unstructured":"Gaweda-Walerych K, et al. Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson\u2019s disease risk in a Polish PD cohort. J Neural Transm. 2008;115(11):1521\u20136.","journal-title":"J Neural Transm"},{"key":"375_CR68","first-page":"208","volume":"2","author":"MC Kenney","year":"1842","unstructured":"Kenney MC, et al. (2014) Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: implications for population susceptibility to diseases. Biochim Biophys Acta. 1842;2:208\u201319.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"375_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41576-020-00284-x","volume":"22","author":"JB Stewart","year":"2021","unstructured":"Stewart JB, Chinnery PF. Extreme heterogeneity of human mitochondrial DNA from organelles to populations. Nat Rev Genet. 2021;22(2):106\u201318.","journal-title":"Nat Rev Genet"},{"key":"375_CR70","doi-asserted-by":"publisher","first-page":"698825","DOI":"10.3389\/fgene.2021.698825","volume":"12","author":"SW Jones","year":"2021","unstructured":"Jones SW, Ball AL, Chadwick AE, Alfirevic A. The role of mitochondrial DNA variation in drug response: a systematic review. Front Genet. 2021;12:698825.","journal-title":"Front Genet"},{"issue":"20","key":"375_CR71","doi-asserted-by":"publisher","first-page":"eabg4000","DOI":"10.1126\/sciadv.abg4000","volume":"7","author":"I Chung","year":"2021","unstructured":"Chung I, et al. Cork-in-bottle mechanism of inhibitor binding to mammalian complex I. Sci Adv. 2021;7(20):eabg4000.","journal-title":"Sci Adv"},{"key":"375_CR72","doi-asserted-by":"publisher","first-page":"e55845","DOI":"10.7554\/eLife.55845","volume":"9","author":"ZA Stephenson","year":"2020","unstructured":"Stephenson ZA, et al. Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I. Elife. 2020;9:e55845.","journal-title":"Elife"},{"issue":"10","key":"375_CR73","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41594-020-0473-x","volume":"27","author":"DN Grba","year":"2020","unstructured":"Grba DN, Hirst J. Mitochondrial complex I structure reveals ordered water molecules for catalysis and proton translocation. Nat Struct Mol Biol. 2020;27(10):892\u2013900.","journal-title":"Nat Struct Mol Biol"},{"key":"375_CR74","doi-asserted-by":"publisher","first-page":"eabc4209","DOI":"10.1126\/science.abc4209","volume":"370","author":"D Kampjut","year":"2020","unstructured":"Kampjut D, Sazanov LA. The coupling mechanism of mammalian respiratory complex I. Science. 2020;370:eabc4209.","journal-title":"Science"},{"issue":"3","key":"375_CR75","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/026988110401800308","volume":"18","author":"T Hirose","year":"2004","unstructured":"Hirose T, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18(3):375\u201383.","journal-title":"J Psychopharmacol"},{"key":"375_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/9780470151808.sc02d05s11","author":"J Pruszak","year":"2009","unstructured":"Pruszak J, Just L, Isacson O, Nikkhah G. Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol. 2009. https:\/\/doi.org\/10.1002\/9780470151808.sc02d05s11.","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"375_CR77","first-page":"152","volume":"2","author":"DS Currle","year":"2007","unstructured":"Currle DS, Hu JS, Kolski-Andreaco A, Monuki ES. Culture of mouse neural stem cell precursors. J Vis Exp. 2007;2:152.","journal-title":"J Vis Exp"},{"key":"375_CR78","unstructured":"(2012) Dissection and Culture of Mouse Dopaminergic and Striatal Explants in Three-Dimensional Collagen Matrix Assays Journal of Visualized Experiments (61) 10.3791\/3691"},{"issue":"48","key":"375_CR79","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1038\/onc.2012.13","volume":"31","author":"GL Robinson","year":"2012","unstructured":"Robinson GL, Dinsdale D, Macfarlane M, Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene. 2012;31(48):4996\u20135006.","journal-title":"Oncogene"},{"issue":"2","key":"375_CR80","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nprot.2014.018","volume":"9","author":"JK Salabei","year":"2014","unstructured":"Salabei JK, Gibb AA, Hill BG. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat Protoc. 2014;9(2):421\u201338.","journal-title":"Nat Protoc"},{"key":"375_CR81","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-biophys-052118-115704","volume":"48","author":"AA Agip","year":"2019","unstructured":"Agip AA, Blaza JN, Fedor JG, Hirst J. Mammalian respiratory complex I through the lens of Cryo-EM. Annu Rev Biophys. 2019;48:165\u201384.","journal-title":"Annu Rev Biophys"},{"issue":"44","key":"375_CR82","doi-asserted-by":"publisher","first-page":"15735","DOI":"10.1073\/pnas.1413855111","volume":"111","author":"JN Blaza","year":"2014","unstructured":"Blaza JN, Serreli R, Jones AJ, Mohammed K, Hirst J. Kinetic evidence against partitioning of the ubiquinone pool and the catalytic relevance of respiratory-chain supercomplexes. Proc Natl Acad Sci USA. 2014;111(44):15735\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"375_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ab.2013.07.018","volume":"442","author":"AJ Jones","year":"2013","unstructured":"Jones AJ, Hirst J. A spectrophotometric coupled enzyme assay to measure the activity of succinate dehydrogenase. Anal Biochem. 2013;442(1):19\u201323.","journal-title":"Anal Biochem"},{"issue":"2","key":"375_CR84","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/anie.201507332","volume":"55","author":"AJ Jones","year":"2016","unstructured":"Jones AJ, et al. A self-assembled respiratory chain that catalyzes NADH oxidation by ubiquinone-10 cycling between complex I and the alternative oxidase. Angew Chem Int Ed Engl. 2016;55(2):728\u201331.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"375_CR85","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1021\/acssynbio.0c00110","volume":"9","author":"O Biner","year":"2020","unstructured":"Biner O, Fedor JG, Yin Z, Hirst J. Bottom-up construction of a minimal system for cellular respiration and energy regeneration. ACS Synth Biol. 2020;9(6):1450\u20139.","journal-title":"ACS Synth Biol"},{"issue":"3","key":"375_CR86","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jmb.2010.12.025","volume":"406","author":"JV Bason","year":"2011","unstructured":"Bason JV, Runswick MJ, Fearnley IM, Walker JE. Binding of the inhibitor protein IF(1) to bovine F(1)-ATPase. J Mol Biol. 2011;406(3):443\u201353.","journal-title":"J Mol Biol"},{"issue":"43","key":"375_CR87","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1038\/onc.2016.99","volume":"35","author":"IR Powley","year":"2016","unstructured":"Powley IR, Hughes MA, Cain K, MacFarlane M. Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex. Oncogene. 2016;35(43):5629\u201340.","journal-title":"Oncogene"},{"issue":"17","key":"375_CR88","doi-asserted-by":"publisher","first-page":"12831","DOI":"10.1074\/jbc.M700438200","volume":"282","author":"SL Kohlhaas","year":"2007","unstructured":"Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem. 2007;282(17):12831\u201341.","journal-title":"J Biol Chem"},{"issue":"5","key":"375_CR89","doi-asserted-by":"publisher","first-page":"e37250","DOI":"10.1371\/journal.pone.0037250","volume":"7","author":"NC Donelson","year":"2012","unstructured":"Donelson NC, et al. High-resolution positional tracking for long-term analysis of Drosophila sleep and locomotion using the \u201ctracker\u201d program. PLoS ONE. 2012;7(5):e37250.","journal-title":"PLoS ONE"},{"issue":"2","key":"375_CR90","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-023-00375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-023-00375-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-023-00375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T01:42:34Z","timestamp":1702863754000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/s13062-023-00375-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1186\/s13062-023-00375-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.02.535223","asserted-by":"object"}]},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}